Drug Profile
Patupilone
Alternative Names: EPO 906; Epothilone BLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics; Epothilones
- Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer; Breast cancer; Colorectal cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
Most Recent Events
- 30 Sep 2012 Novartis completes a phase II trial in Prostate cancer (Hormone-refractory, Metastatic disease) in Australia, Belgium, France, Germany, Italy, Singapore, Spain and USA (NCT00411528)
- 13 Jun 2012 Novartis completes a phase I trial of patupilone in combination with everolimus in Solid tumours (refractory disease) in USA (NCT00496600)
- 27 Aug 2011 Novartis completes a phase I trial in late-stage solid tumours in US (NCT00420524)